Gastrointestinal Cancer | Specialty

IDO Inhibitor/Chemo Combo Shows Early Promise in Advanced Pancreatic Cancer

April 27th 2016

Nathan Bahary, MD, discusses results of a study that showed that the combination of indoximod with standard chemotherapy yielded a response rate of 42% as a first-line therapy for patients with metastatic pancreatic adenocarcinoma.

SIRFLOX Study Design Confounds Primary Efficacy Findings

April 27th 2016

Navesh K. Sharma, DO, PhD, discusses findings on a study looking at the addition of Yttrium-90 resin microspheres to standard frontline FOLFOX-based chemotherapy with or without bevacizumab in liver metastatic colorectal cancer.

Dr. Geschwind on Locoregional Therapy for Patients With Liver Cancer

April 26th 2016

Jeff Geschwind, MD, professor and chairman, Radiology and Biomedical Imaging, Yale Cancer Center, discusses locoregional treatment options for patients with hepatocellular carcinoma (HCC).

Novel Agents on Horizon for Advanced HCC

April 26th 2016

A number of novel therapies are currently being explored as second-line treatments for patients with advanced hepatocellular carcinoma, including a host of targeted therapies and various immune checkpoint inhibitors.

Immunotherapy Doubts Fading in GI Cancers

April 26th 2016

Immunotherapy approaches are showing early signs of activity against a range of gastrointestinal cancers, defying the skeptical view that these tumors would not respond to the emerging agents succeeding in other malignancies.

Dr. Douglas Evans on Neadjuvant Therapy for Pancreas Cancer

April 26th 2016

Douglas B. Evans, MD, FACS, Chair, Professor, Donald C. Ausman Family Foundation Professor of Surgery, Medical College of Wisconsin, discusses how to appropriately sequence therapies for pancreatic cancer.

Multidisciplinary Treatment a Growing Need in Liver Cancer

April 26th 2016

Michael Choti, MD, explains the impact of advancements in the treatment of patients with liver cancer and how building on them will require all oncology professionals to work as a team.

Precision Medicine Vital to Value-Based GI Cancer Care

April 23rd 2016

Cancer care is shifting from a consumption to a value-based model, and precision oncology should play a vital role in that process by helping to deliver more effective therapies with more manageable pricing profiles.

Numerous Frontline CRC Options Allow Individualized Approach

April 23rd 2016

Given the numerous available treatment options, the most important issue in frontline colorectal cancer care is clarifying the goals of therapy.

Dr. Bekaii-Saab on Active Agents for the Treatment of Colorectal Cancer

April 23rd 2016

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses about 2 agents, regorafenib and TAS-102, for the treatment of patients with treat colorectal cancer.

Treating GI Cancers Is a “Team Sport,” Conference Leader Says

April 23rd 2016

John L. Marshall, MD, discusses how the management of patients with gastrointestinal cancers requires a multidisciplinary approach.

Genomics Studies Opening Up Fresh Options for CRC Research

April 22nd 2016

Raju Kucherlapati, PhD, serves as principal investigator of a Genome Characterization Center as part of The Cancer Genome Atlas program, a National Cancer Institute initiative aimed at defining the copy number changes and structural aberrations present in many different cancer types.

The Future of Immunotherapy in HCC

April 22nd 2016

Advances in Systemic Therapy for HCC

April 22nd 2016

Advances in Local-Regional Therapies for HCC

April 22nd 2016

Major Advances in Treatment of Hepatitis C Virus

April 22nd 2016

Assessing Response to Sorafenib in Liver Cancers

April 22nd 2016

Managing Toxicities in Advanced HCC

April 22nd 2016

Practical Views on Sorafenib in HCC

April 22nd 2016

Systemic Therapy for Advanced HCC

April 22nd 2016